{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:55:14Z","timestamp":1791312914061,"version":"4.3.1"},"reference-count":18,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2014,9,25]],"date-time":"2014-09-25T00:00:00Z","timestamp":1411603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"French Medicines Agency (Ansm)"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Fundamemntal Clinical Pharma"],"published-print":{"date-parts":[[2015,2]]},"abstract":"Abstract<\/jats:title>To assess the incidence of hospital admissions related to adverse drug reactions (ADR<\/jats:styled-content>s) in F<\/jats:styled-content>rance and the frequency of preventable ADR<\/jats:styled-content>s in F<\/jats:styled-content>rance, a prospective study was conducted among a representative randomly selected sample of medical wards in public hospitals between D<\/jats:styled-content>ecember 2006 and J<\/jats:styled-content>une 2007; all patients admitted during a 2\u2010week period were included. An ADR<\/jats:styled-content>\u2010related hospitalization case was defined as a hospital admission because of an ADR<\/jats:styled-content>, and an independent committee reviewed and validated all potential cases. Preventability was assessed using the F<\/jats:styled-content>rench ADR<\/jats:styled-content> preventability scale. Data were extrapolated to the population of F<\/jats:styled-content>rance. Among 2692 admissions, 97 were related to an ADR<\/jats:styled-content> (incidence 3.6%, 95% confidence interval, CI<\/jats:styled-content> [2.8\u20134.4]). Patients admitted for an ADR<\/jats:styled-content> were significantly older than those admitted for other reasons (P<\/jats:italic>\u00a0<\u00a00.001). A third (32.0%) of ADR<\/jats:styled-content>\u2010related hospitalizations were \u2018preventable\u2019, 16.5% \u2018potentially preventable\u2019. Drug interactions accounted for 29.9% of ADR<\/jats:styled-content>\u2010related hospitalizations. The most frequent causes of ADR<\/jats:styled-content>\u2010related hospitalizations were vascular disorders (20.6%), mainly bleeding complications, central nervous system disorders (11.3%), gastrointestinal disorders, and general disorders (9.3%). Antithrombotic and antineoplastic agents were the most frequently involved (12.6% each), followed by diuretics and analgesics (9.0% each). Vitamin\u2010K\u2010antagonists (VKA<\/jats:styled-content>s) were the most common drugs associated with admission. The estimated annual number of ADR<\/jats:styled-content>\u2010related hospitalizations in F<\/jats:styled-content>rance was 143\u00a0915 (95% CI<\/jats:styled-content> [112\u00a0063\u2013175\u00a0766]). ADR<\/jats:styled-content>s were a significant cause of hospital admission in 2006\u20132007, in particular those due to VKA<\/jats:styled-content>s. As new oral anticoagulants (NOAC<\/jats:styled-content>s) have been marketed, more attention needs to be paid to ensure a safe use of antithrombotic agents.<\/jats:p>","DOI":"10.1111\/fcp.12088","type":"journal-article","created":{"date-parts":[[2014,7,3]],"date-time":"2014-07-03T04:22:55Z","timestamp":1404361375000},"page":"106-111","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":120,"title":["Incidence of hospital admissions due to adverse drug reactions in F<\/scp>rance: the EMIR<\/scp> study"],"prefix":"10.1111","volume":"29","author":[{"given":"Anne","family":"B\u00e9nard\u2010Laribi\u00e8re","sequence":"first","affiliation":[{"name":"CHU Bordeaux Service de pharmacologie F\u201033000 Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghada","family":"Miremont\u2010Salam\u00e9","sequence":"additional","affiliation":[{"name":"CHU Bordeaux Service de pharmacologie F\u201033000 Bordeaux France"},{"name":"INSERM U657 F\u201033000 Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie\u2010Christine","family":"P\u00e9rault\u2010Pochat","sequence":"additional","affiliation":[{"name":"CHU Poitiers Service de pharmacologie F\u201086000 Poitiers France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernelle","family":"Noize","sequence":"additional","affiliation":[{"name":"CHU Bordeaux Service de pharmacologie F\u201033000 Bordeaux France"},{"name":"INSERM U657 F\u201033000 Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Haramburu","sequence":"additional","affiliation":[{"name":"CHU Bordeaux Service de pharmacologie F\u201033000 Bordeaux France"},{"name":"INSERM U657 F\u201033000 Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the EMIR Study Group on behalf of the French network of pharmacovigilance centres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,9,25]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2007.06.030"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-10-287"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/106002809302700702"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1L037"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.15.1200"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1998.00667.x"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6904-7-9"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.329.7456.15"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.320.7241.1036"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1998.tb138996.x"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1565"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629020-00006"},{"key":"e_1_2_9_14_1","first-page":"20","article-title":"Incidence of hospital admissions due to adverse drug reactions: the EMIR study","volume":"22","author":"Haramburu F.","year":"2008","journal-title":"Fundam. Clin. Pharmacol."},{"key":"e_1_2_9_15_1","first-page":"885","article-title":"Hospital admissions due to adverse drug reactions: EMIR, a Nationwide Study","volume":"31","author":"Miremont\u2010Salam\u00e9 G.","year":"2008","journal-title":"Drug Saf."},{"key":"e_1_2_9_16_1","unstructured":"World Health Organization.Safety of medicines \u2013 a guide to detecting and reporting adverse drug reactions \u2013 why health professionals need to take action. WHO\/EDM\/QSM\/2002.2. Available from:http:\/\/apps.who.int\/medicinedocs\/en\/d\/Jh2992e\/1.html-Jh2992e[accessed 11 December 2013]."},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.2515\/therapie:2005005"},{"key":"e_1_2_9_18_1","unstructured":"Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9.Les anticoagulants en France en 2012: Etat des lieux et surveillance. Available from:http:\/\/ansm.sante.fr\/content\/download\/42641\/553644\/version\/1\/file\/Rapport_Anticoagulants_Juillet2012.pdf[accessed 27 May 2014]."},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2013.03.006"}],"container-title":["Fundamental & Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ffcp.12088","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/fcp.12088","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T15:27:25Z","timestamp":1696346845000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/fcp.12088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,25]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["10.1111\/fcp.12088"],"URL":"https:\/\/doi.org\/10.1111\/fcp.12088","archive":["Portico"],"relation":{},"ISSN":["0767-3981","1472-8206"],"issn-type":[{"value":"0767-3981","type":"print"},{"value":"1472-8206","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,25]]},"assertion":[{"value":"2014-04-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-06-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-09-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}